Turn on cookies to sign in
Signing in saves your progress to your Curie account. We can only do that with cookies on — turn them on to continue.
A folate supplement is showing real-world promise for hard-to-treat psychiatric patients. A retrospective study of 60 treatment-experienced patients found that adding L-methylfolate (Deplin) to existing psychiatric regimens significantly reduced overall symptom burden — with executive function showing the biggest and earliest gains. Notably, patients who had tried more medications before starting Deplin saw even greater improvements.
For patients who haven't fully responded to standard psychiatric medications, a prescription-grade folate supplement may offer an extra boost. A real-world retrospective study of 60 treatment-experienced psychiatric patients found that adding L-methylfolate (Deplin) to their existing regimens led to significant reductions in overall symptom burden across depression, anxiety, and executive function measures.
Executive function showed the largest and earliest improvement, followed by more gradual gains in depression and anxiety scores. Interestingly, the more medications a patient had tried before starting Deplin, the greater their symptom reduction — suggesting it may be especially useful for those with more complex treatment histories.
By the Numbers:
Why it matters: L-methylfolate is already used clinically, but its incremental benefit in treatment-experienced patients hasn't been well characterized. While the study's observational design limits firm conclusions, the findings give clinicians a useful signal for patients still struggling despite existing treatment.
